PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Age 1-65 years at the time of kidney transplant 2. Biopsy proven diagnosis of primary FSGS or minimal change disease 3. History of nephrotic syndrome (proteinuria, edema, hypoalbuminemia) 4. First kidney transplant or second or third transplant with a history of recurrent FSGS in the first or second kidney transplant. 5. The patient (if ≥18 years old) or the child's parent or guardian must be able and willing to give written informed consent and comply with the requirements of the study protocol. Patient assent if \<18 years old will be required per local IRB requirements. 6. Negative urine pregnancy test prior to randomization (for females who are post-menarche). 7. Males and females of reproductive potential (sexually active in boys or post-menarche in girls) must agree to use an acceptable method of birth control during treatment and for twelve months (1 year) after completion of treatment with rituximab. An individual who meets any of the following criteria will be excluded from participation in this study: 1\. Known genetic cause of FSGS 2. Patients with FSGS secondary to another condition (obesity, viral infection, medications, etc.) 3. 4. Received rituximab within 1 year prior to transplant 5. Known hypersensitivity to rituximab, to any of its excipients, or to murine proteins 6. History of severe allergic or anaphylactic reactions to humanized or murine m…